1. At a Glance
There are pharmaceutical companies that quietly manufacture tablets in industrial estates and then there are companies that suddenly wake up one fine quarter and start behaving like they swallowed an energy drink mixed with investor optimism.
Kilitch Drugs (India) Ltd currently belongs to the second category.
In Q4 FY26, the company reported consolidated quarterly revenue of ₹89.6 crore versus ₹61 crore last year, a 46% jump. PAT surged nearly 40% YoY to ₹14.9 crore. Operating margins expanded sharply to 25% from 24% in the previous March quarter and just 11% in Dec 2025. Suddenly, a company once treated like a forgotten smallcap pharma exporter is now throwing around bonus issues, rights issues, Ethiopia government contracts, greenfield capex plans, and aggressive balance sheet expansion.
The market clearly noticed.
But here is where the detective story begins.
Whenever a small pharma company suddenly accelerates revenue growth while simultaneously increasing receivables, borrowing, capital work-in-progress, and promoter financing activity, investors should stop clapping for five minutes and start reading footnotes like forensic accountants.
Because the numbers here are both exciting and slightly uncomfortable at the same time.
The company’s consolidated trade receivables have exploded to ₹120 crore equivalent (₹12,017 lakh) from ₹84.7 crore last year. Debtor days have climbed to 186 days. Working capital days ballooned to 130 days. Borrowings almost doubled to nearly ₹89 crore.
That means the company is growing, yes.
But it is also increasingly financing customers.
And in export-focused pharma businesses, especially in African markets, that becomes a dangerous game very quickly.
To understand the story properly, one needs to look at what exactly Kilitch Drugs is trying to become.
This is not merely a domestic generic pharma player anymore. The company is attempting a transition toward a broader export-led formulation business with manufacturing presence in Ethiopia and an ambitious greenfield injectable project in Khopoli, Maharashtra. Management is effectively betting that Africa plus manufacturing scale plus export registrations can create a meaningful long-term pharma platform.
The interesting part?
The company’s export registrations expenditure jumped massively over the last few years, touching ₹1,977 lakh in FY25 from merely ₹476 lakh in FY23.
That means they are aggressively registering products globally.
The worrying part?
Export-led pharma businesses can either become wealth creators or working-capital graveyards depending on how collections behave.
And Kilitch’s receivable trends are beginning to ask difficult questions.
Another fascinating development is the capital allocation behavior.
The company announced:
- ₹50 crore rights issue
- ₹100 crore greenfield project
- 1:1 bonus issue
- authorised capital increase to ₹40 crore
All within a relatively compressed timeframe.
This is either:
- A management team preparing aggressively for scale-up
Or:
2. A management team running faster than its balance sheet comfortably allows.
Which one is true?
That is the real puzzle.
And the funniest part?
Despite all this excitement, the stock still trades at roughly 21x earnings versus industry median P/E above 30x. The market is basically saying:
“Nice growth. Now prove the cash actually arrives.”
Fair enough.
Because revenue is vanity.
Cash flow is reality.
And debtor days are where pharma dreams occasionally go to die.
So the big question becomes:
Is Kilitch Drugs building the next export pharma success story?
Or is it building a beautifully decorated receivables warehouse?
Let’s investigate.
2. Introduction
Kilitch Drugs (India) Ltd was incorporated in 1978, which means this company has existed long enough to witness multiple pharma cycles, export booms, regulatory shifts, and probably enough FDA paperwork to fill a small library.
The business operates across pharmaceutical formulations including:
- tablets
- capsules
- injectables
- dry syrups
- nasal products
- herbal products
- medical devices
The company exports heavily into Africa, Asia, CIS countries, and Latin America. Africa remains particularly important because Kilitch has an operational manufacturing presence in Ethiopia through its subsidiary Kilitch Estro Biotech PLC, where it owns approximately 67%.
And this Ethiopia angle is not a small side story.
It may actually be the central investment thesis.
In February 2024, the Ethiopia subsidiary won a pharmaceutical supply tender worth approximately USD 9.13 million.
Now pause and think carefully.
A ₹640 crore market cap company securing overseas government-linked pharma contracts while simultaneously building manufacturing infrastructure is exactly the kind of thing that excites smallcap investors.
But such opportunities also create operational strain.
Why?
Because export pharma businesses need:
- registrations
- inventory
- compliance
- distributor networks
- collection
